4 min read
|
Saved February 14, 2026
|
Copied!
Do you care about this?
The author critiques the challenges of getting listed on centralized exchanges (CEXs), highlighting predatory practices and excessive fees. They express optimism about Hyperliquid's approach to spot markets but note that recent listings have struggled with volume and price stability.
If you do, here's more
The article dives into the complexities surrounding spot listings on Hyperliquid compared to centralized exchanges (CEX). The author, a founder, shares insights from their experience, criticizing the typical practices of CEX listings. They highlight strategies that encourage low initial pricing and marketing tactics that seem more focused on benefiting the exchange than the token's long-term health. Listing fees can exceed $200,000, often disguised as technical costs. The author expresses a strong belief that many CEX listings harm the crypto space, recalling their own experience with a listing that was only pursued due to favorable terms.
The conversation shifts to Hyperliquid's spot market, where the author expresses optimism about the technology and its potential to attract diverse market participants. However, reality sets in as they observe that many spot listings struggle to maintain volume and price stability. They mention a recent project ($KNTQ) that shows promise due to its strong team and solid plans for token value, indicating potential for Hyperliquid's market mechanisms to function effectively. Despite building on Hyperliquid and managing a community, the author remains concerned about the liquidity available for their own token, $PEAR, on Arbitrum, calling the chain effectively "dead" for spot trading.
In the conclusion, the author mentions plans for migrating the $PEAR token to new venues, including Hyperliquid, with a promise of a 1:1 conversion for holders. They note that buybacks for this token will start following a governance vote, hinting at a cautious but strategic approach to navigating the challenges of crypto markets.
Questions about this article
No questions yet.